A manufacturer-sponsored study generates intriguing results but misses the mark for changing practice.
The Canadian CT Head Rule, New Orleans Criteria, and the National Emergency X-Radiography Utilization Study II Rule are 100% sensitive for traumatic head injury requiring neurosurgical intervention (NEJM JW Emerg Med Jan 2006 and JAMA 2005; 294:1519), but their specificity is lower, and their widespread implementation may have increased head computed tomography (CT) use in some settings. In a prospective, observational, manufacturer-sponsored study, investigators assessed whether quantitative electroencephalography (QEEG) using a proprietary handheld device could improve specificity.
The researchers enrolled a convenience sample of 152 adult patients with minor head trauma who had head CT ordered as part of their routine care at two trauma c…
Reviewing Author
DisclosuresConsultant/Advisory BoardPortola Pharmaceuticals, Inc.
Speaker’s BureauPeerView Institute for Medical Education
Grant/Research SupportAgency for Healthcare Research and Quality; CDC; NIH–National Center for Advancing Translational Sciences; NIH–National Institute of Allergy and Infectious Diseases (NIAID); NIH–NIAID–Antibacterial Resistance Leadership Group; Merck; Pfizer; Boehringer-Ingelheim; Shire; Portola Pharmaceuticals, Inc.; Novartis; bioMérieux; Siemens; Rapid Pathogen Screening; Magnolia; Stago; Innovative Biosensors; Molecular Detection, Inc.; Dyax Corp.; Trius Pharmaceuticals
DisclosuresConsultant/Advisory BoardPortola Pharmaceuticals, Inc.
Speaker’s BureauPeerView Institute for Medical Education
Grant/Research SupportAgency for Healthcare Research and Quality; CDC; NIH–National Center for Advancing Translational Sciences; NIH–National Institute of Allergy and Infectious Diseases (NIAID); NIH–NIAID–Antibacterial Resistance Leadership Group; Merck; Pfizer; Boehringer-Ingelheim; Shire; Portola Pharmaceuticals, Inc.; Novartis; bioMérieux; Siemens; Rapid Pathogen Screening; Magnolia; Stago; Innovative Biosensors; Molecular Detection, Inc.; Dyax Corp.; Trius Pharmaceuticals